The founding of ALX Oncology was based upon technology invented at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1
ALX Oncology is an independent, private biotechnology company. Since May 2015, we have raised a total of $61 million in funding, which was led by venBio and joined by Lightstone Ventures and Stanford University.
Senior Director, Finance and Controller
Chief Business Officer
Vice President, Operations
Senior Director, Clinical Science
Director of Strategy and Corporate Development
President and Chief Executive Officer
Chief Medical Officer
Vice President, Protein Science
Jonathan Sockolosky, Ph.D.
Vice President, Chemistry, Manufacturing, and Controls
Chief Scientific Officer
Acting General Counsel
- Kipp Weiskopf, et al. Science 341, 88 (2013);
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23722425